Journal of Cancer Research and Therapeutics

REVIEW ARTICLE
Year
: 2011  |  Volume : 7  |  Issue : 4  |  Page : 399--407

Monoclonal antibodies in hematological malignancies: Past, present and future


I Tazi, H Nafil, L Mahmal 
 Department of Hematology, Chu Mohamed VI, Cadi Ayyad University, Marrakech, Morocco

Correspondence Address:
I Tazi
Department of Hematology, Chu Mohamed VI, Cadi Ayyad University, Marrakech
Morocco

Much progress has been made during the last few decades in the treatment of hematological malignancies. Monoclonal antibodies (MoAbs) represent a major advance toward a targeted therapy that can dramatically improve the antitumor effect with a substantial reduction of toxicity derived from therapy. Unlike many small molecules, MoAbs offer unique target specificity. Several MoAbs are now in clinical use for hematologic malignancies therapy, and many others are currently undergoing clinical evaluation. This review summarizes the state-of-the-art MoAbs treatment, beginning with an overview of the scientific background to their synthesis, mechanism of action and choice of target antigen, mainly focusing on those antibodies that are currently in use in clinical practice. Despite these advances, significant challenges remain in the identification of optimal cellular targets, antibody forms and treatment schedules for therapeutic applications.


How to cite this article:
Tazi I, Nafil H, Mahmal L. Monoclonal antibodies in hematological malignancies: Past, present and future.J Can Res Ther 2011;7:399-407


How to cite this URL:
Tazi I, Nafil H, Mahmal L. Monoclonal antibodies in hematological malignancies: Past, present and future. J Can Res Ther [serial online] 2011 [cited 2020 Jul 9 ];7:399-407
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2011;volume=7;issue=4;spage=399;epage=407;aulast=Tazi;type=0